Annual report [Section 13 and 15(d), not S-K Item 405]

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.25.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Common Stock
Additional Paid-in- Capital
Treasury Stock
Accumulated Other Comprehensive Income
Accumulated Deficit
Total
Beginning balance at Dec. 31, 2022 $ 57 $ 297,265 $ (7,625) $ 1,126 $ (180,751) $ 110,072
Beginning balance (in shares) at Dec. 31, 2022 54,653          
Increase (Decrease) in Stockholders' Equity            
Net loss         (8,223) (8,223)
Issuance of shares in connection with stock option exercise $ 2 2,648       $ 2,650
Issuance of shares in connection with stock option exercise (in shares) 1,674         1,673
Issuance of shares in connection with restricted stock units vesting $ 1         $ 1
Issuance of shares in connection with restricted stock units vesting (in shares) 1,078          
Issuance of shares in connection with BOD fees   23       23
Issuance of shares in connection with BOD fees (in shares) 5          
Issuance of shares in connection with ESPP   483       $ 483
Issuance of shares in connection with ESPP (in shares) 114         114
Share-based compensation   12,479       $ 12,479
Stock repurchase   (24) $ (4,287)     (4,311)
Stock repurchase (in shares) (1,221)   (1,221)      
Actuarial loss on defined benefit plan       (305)   (305)
Unrealized loss on deferred compensation trust assets       (38)   (38)
Ending balance at Dec. 30, 2023 $ 60 312,874 $ (11,912) 783 (188,974) 112,831
Ending balance (in shares) at Dec. 30, 2023 56,303          
Increase (Decrease) in Stockholders' Equity            
Net loss         (40,601) (40,601)
Issuance of shares in connection with restricted stock units vesting $ 1 (471)       (470)
Issuance of shares in connection with restricted stock units vesting (in shares) 847          
Issuance of shares in connection with BOD fees   43       43
Issuance of shares in connection with BOD fees (in shares) 34          
Issuance of shares in connection with ESPP   359       $ 359
Issuance of shares in connection with ESPP (in shares) 260         260
Share-based compensation   12,731       $ 12,731
Stock repurchase     0      
Actuarial loss on defined benefit plan       185   185
Officers and directors stock purchase plan   10       10
Officers and directors stock purchase plan (in shares) 10          
Foreign currency adjustments       87   87
Ending balance at Dec. 28, 2024 $ 61 $ 325,546 $ (11,912) $ 1,055 $ (229,575) $ 85,175
Ending balance (in shares) at Dec. 28, 2024 57,454